INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in iTonic Holdings Ltd (f/k/a Pheton Holdings Ltd) of Class Action Lawsuit and Upcoming Deadlines

Pomerantz LLP filed a securities class action against iTonic Holdings (formerly Pheton Holdings), alleging a pump-and-dump scheme involving company officers, its auditor and IPO underwriters. The complaint alleges promoters circulated baseless claims, including a fabricated Gilead Sciences acquisition rumor, before Pheton shares collapsed approximately 95% in one trading session on July 29, 2025. Investors who acquired shares during the class period have until September 28, 2026 to seek appointment as lead plaintiff.

Analysis

This is primarily a liquidity and market-structure event for ITOC, not a read-through to GILD. The allegation involving a fabricated Gilead transaction creates no fundamental exposure for GILD, but may produce brief headline-driven noise that is more likely an opportunity for liquidity providers than a directional signal. ITOC’s investability is impaired: fraud allegations extending to management, auditor, and IPO underwriters raise the probability of prolonged disclosure gaps, financing constraints, exchange-compliance risk, and a structurally wider cost of equity.

In the next days through the September 28 lead-plaintiff deadline, ITOC may see elevated retail turnover and intermittent short-covering, especially if float is constrained. Those rallies should not be mistaken for a fundamental reset; litigation announcements are claimant-solicitation events and do not independently validate damages or recovery. The more consequential 1-3 month catalysts are any Nasdaq deficiency notice, auditor resignation/restatement, SEC action, related-party financing disclosure, or evidence that the alleged promotional network was linked to insiders.

The non-obvious spillover is to the small-cap IPO ecosystem rather than biotech: any credible linkage among issuer, auditor, and placement agents can increase diligence discounts for similarly structured microcap offerings and reduce aftermarket sponsorship. A short is operationally unattractive unless borrow is confirmed and position sizing assumes gap risk; post-collapse securities can remain volatile despite poor long-run expected value. GILD should be neutral-to-ignored unless the company makes a specific statement or a verifiable commercial/legal connection emerges.

Key Decisions for Investors

• Do not initiate a directional GILD position on this headline. Treat any sub-1% sympathy decline unaccompanied by company disclosure as a potential mean-reversion opportunity, not evidence of transaction or litigation exposure.
• Place ITOC on a restricted/watch list through the September 28 deadline and require confirmed borrow, current float data, and intraday liquidity review before considering any short exposure. Avoid naked shorting given squeeze and halt risk.
• If ITOC rallies more than 30% on promoter activity or lawsuit-related headlines without audited financial disclosures, consider a small, tightly risk-capped short only after borrow is secured; cover on a 20% adverse move or on verified strategic financing/independent governance remediation.
• Monitor Nasdaq notices, SEC enforcement filings, auditor communications, and amended registration statements over the next 1-3 months. A formal regulatory action or auditor withdrawal would validate a renewed downside thesis; clean audited filings and independent-board remediation would falsify it.